What Is the Newest Treatment for Fuchs Dystrophy?

The treatment landscape for Fuchs endothelial corneal dystrophy (Fuchs dystrophy) has shifted dramatically in recent years, moving away from full-thickness corneal transplants toward less invasive surgeries, cell-based therapies, and drugs that target the genetic root of the disease. The most talked-about newer approach is Descemet stripping only (DSO), a procedure that removes the diseased inner layer of the cornea without transplanting donor tissue, relying instead on the eye’s own cells to regenerate. Meanwhile, cultured human corneal endothelial cell injection has shown durable results out to ten years in early trials, and at least one small-molecule eye drop designed to attack the underlying genetic defect has entered Phase II clinical testing. No single “newest” treatment defines the field right now; instead, several advances are converging at once, each suited to different stages and severities of the disease.

Why Fuchs Dystrophy Is Hard to Treat

The cornea’s innermost layer, the endothelium, is a single sheet of cells that pumps fluid out of the cornea to keep it clear. In Fuchs dystrophy, these cells gradually die off and are replaced by abnormal bumps called guttae on the membrane beneath them. Because human corneal endothelial cells barely divide in adulthood, the body cannot replace what is lost. The cornea swells, vision gets hazy, and eventually a transplant becomes necessary. For decades, the standard surgical fix was a full-thickness corneal graft, then later a partial-thickness transplant called DMEK (Descemet membrane endothelial keratoplasty), which replaced just the damaged back layer with donor tissue. DMEK remains the gold-standard surgery and produces excellent visual outcomes, though it still requires donor tissue, carries a risk of graft rejection, and demands lifelong steroid eye drops.

The genetic picture has sharpened considerably. The majority of Fuchs cases are linked to an expanded trinucleotide repeat (a stuttering stretch of DNA) inside a gene called TCF4. When that repeat grows beyond roughly 50 copies, risk for Fuchs dystrophy jumps dramatically.¹ The expanded repeat produces toxic RNA that clumps into structures called foci inside the cell nucleus, trapping splicing proteins that cells need for normal gene processing.² Understanding this mechanism has opened the door to therapies that go after the disease’s cause rather than just managing its symptoms.

Descemet Stripping Only

DSO is the procedure generating the most excitement among corneal surgeons right now. The idea sounds almost too simple: instead of transplanting new tissue, the surgeon peels away a small central disc of the diseased Descemet membrane and guttae, then waits for healthier endothelial cells from the periphery of the cornea to migrate inward and repopulate the stripped zone. No donor tissue is needed, which eliminates graft rejection entirely.

Early case reports showed that DSO could produce lasting corneal clarity. One patient achieved perfect best-corrected visual acuity by three months after the procedure, and that result held stable through five years of follow-up.³ A more recent case report tracked a patient for a full decade after DSO; the cornea eventually did need a DMEK, but the patient enjoyed nearly ten years of good vision and healthy cell density before that point.⁴ That case also showed an important safety net: if DSO eventually fails, a conventional transplant can still be performed successfully afterward.

A comparative analysis found that DSO achieved visual outcomes equivalent to DMEK in well-selected patients while reducing complication rates.⁵ The catch is patient selection: DSO works best when the guttae are concentrated centrally and the peripheral endothelium is still relatively healthy. Patients whose guttae extend from limbus to limbus, with no reserve of preserved peripheral cells, are not good candidates.⁶

How Peripheral Cells Fill the Gap

DSO’s success depends on cell migration, and researchers have been studying exactly how that happens. In organ culture, corneal endothelial cells from the periphery begin migrating inward within about four days after the barrier is disrupted, and migration continues for at least a month.⁷ Interestingly, a second, faster-growing population of cells emerges from near the limbus (the border between the cornea and the white of the eye) after about three weeks, suggesting there may be a reservoir of less-differentiated cells that can be recruited.

There is also a counterintuitive finding about Fuchs cells themselves. In lab studies, endothelial cells from Fuchs patients actually move faster than normal cells, both in intact tissue and in culture.⁸ The trade-off is that those faster cells tend to adopt a more fibroblastic shape, which may make them less effective as pump cells. This tension between migration speed and cell quality is one reason researchers are exploring drugs that can guide regeneration in a more controlled way.

ROCK Inhibitors as a Booster

Rho-associated protein kinase (ROCK) inhibitors are a class of eye drops originally developed for glaucoma. Researchers noticed that they also promote corneal endothelial cell migration and proliferation, which made them natural companions for DSO. In lab studies, the ROCK inhibitor ripasudil switched on genes related to cell division, cell movement, and the endothelium’s pumping function in both Fuchs-affected and normal tissue.⁹

In clinical practice, the related ROCK inhibitor netarsudil has been used after DSO in a prospective study. Eyes that received netarsudil drops after the procedure cleared faster, achieved better visual acuity, and had higher central endothelial cell counts at six months compared with eyes that did not receive the drops. Cell counts continued rising beyond twelve months and remained higher in the netarsudil group.¹⁰ That said, DSO can succeed without ROCK inhibitors: a separate study of fifteen eyes treated with DSO alone found that fourteen of fifteen achieved corneal clearance, with a mean time to clearance of about eight and a half weeks.¹¹ The clearance took longer without the drops, but the overall success rate was comparable. This matters in countries where ROCK inhibitors are not yet approved or available.

Engineered Growth Factors

Another strategy to speed up endothelial healing after DSO involves engineered growth factors. An engineered form of fibroblast growth factor called TTHX1114 was tested on human corneas in organ culture after simulated DSO. Corneas treated with TTHX1114 healed about 81% of the stripped area in fourteen days, compared with roughly 30% in untreated corneas.¹² The treated corneas formed a more complete, contiguous layer of functional-looking cells. This is still preclinical work, but it points toward a future where DSO could be paired with a growth-factor eye drop to shorten recovery and improve outcomes.

Cultured Endothelial Cell Injection

Perhaps the most striking advance in Fuchs treatment is the injection of lab-grown human corneal endothelial cells directly into the eye. Pioneered by a team in Japan, the approach involves culturing donor endothelial cells in the lab to multiply them from a single donor cornea into enough cells for dozens of patients, then injecting the cells into the front chamber of the eye. The patient lies face-down for several hours to let the cells settle and attach to the back surface of the cornea.

Long-term data are now available. At five years after injection, about 93% of treated eyes maintained corneal transparency, roughly 80% had a cell density above 1,000 cells per square millimeter, and about 86% had improved visual acuity. At ten years, transparency was maintained in about 84% of eyes, with no severe adverse reactions reported across the study period.¹³ A separate study evaluating a similar approach found that at two years, cell density exceeded 2,400 cells per square millimeter and corneal thickness was under 550 micrometers, both indicators of a well-functioning endothelium. Gene analysis confirmed that the transplanted cells maintained their endothelial character over time.¹⁴

Cell injection therapy is not yet widely available outside clinical trials, but it addresses two major limitations of conventional transplants: it dramatically multiplies the utility of each donor cornea (potentially treating many patients from one donor) and eliminates the need for delicate graft handling in the operating room. Whether it will eventually replace DMEK for all comers or remain a complement to it is still an open question.

Targeting the Genetic Root With RNA Therapies

Because most Fuchs dystrophy traces back to a toxic RNA produced by the expanded TCF4 repeat, several groups are developing molecules that bind directly to that repeat and neutralize it. Antisense oligonucleotides, short synthetic strands of modified DNA or RNA, can enter corneal endothelial cells, latch onto the expanded CUG repeat in the TCF4 transcript, and block the formation of toxic RNA foci. In human Fuchs corneas tested ex vivo, locked nucleic acid oligonucleotides disrupted foci and partially restored normal splicing patterns in multiple downstream genes.¹⁵

A different chemistry, morpholino peptide conjugates, has also been shown to enter corneal endothelial cells and block CUG RNA foci associated with the disease. The peptide portion of these molecules is optimized for crossing cell membranes, which is a persistent challenge for getting large therapeutic molecules into the eye’s inner layers.¹⁶ These approaches remain preclinical, but they represent a genuinely disease-modifying strategy rather than a surgical workaround.

The furthest along in the clinic is DT-168, a small molecule developed as an eye drop that selectively targets the expanded CTG repeat in TCF4. It is currently in Phase II trials for Fuchs dystrophy. If successful, it would be the first topical drug to treat the genetic cause of the disease rather than managing its consequences.

Gene Editing and Advanced Delivery

CRISPR-based gene editing has been applied to Fuchs dystrophy cells in the lab. Researchers used CRISPR/Cas9 to delete the expanded CTG repeat from immortalized Fuchs cells, creating an isogenic cell line without the expansion. Comparing the edited and unedited cells revealed distinct changes in the protein landscape driven by the repeat, confirming that the expansion alters the cell’s biology in measurable ways and suggesting that correcting it could reverse those changes.¹⁷

Getting gene-editing tools into the corneal endothelium in a living eye is a separate challenge. A recent study described charge-altering releasable transporters (CARTs), nanoparticles that can deliver RNA cargo, including CRISPR/Cas9 components, selectively to corneal endothelial cells. In animal models, CART nanoparticles achieved corneal gene editing, could be redosed safely, and successfully transfected human donor corneal endothelial cells in vitro as well as non-human primate cells in vivo.¹⁸ The ability to redose is significant, because many viral delivery systems can only be used once before the immune system blocks subsequent doses. This platform could eventually enable repeated gene-editing treatments delivered as an injection into the front of the eye.

AI-Assisted Diagnosis and Monitoring

New treatments are only useful if clinicians can accurately stage the disease and track how patients respond. Traditional specular microscopy, which photographs the endothelial cell layer, has limitations in Fuchs dystrophy because guttae scatter light and confuse the built-in analysis software. A study comparing AI-derived measurements to standard microscope software found that the software significantly overestimated cell density in Fuchs patients, reporting an average of about 2,216 cells per square millimeter when the AI-corrected figure was closer to 1,322.¹⁹ The AI system also identified guttae area ratio as the measurement that tracked most closely with clinical grading, giving clinicians a more reliable metric for staging the disease.

Deep learning models trained on widefield specular microscopy images have achieved strong accuracy in detecting Fuchs dystrophy, with one model reaching an area under the curve of 0.96, sensitivity of 0.91, and specificity of 0.91 on its training dataset.²⁰ Performance dropped on an external validation set, which is common for early-stage AI tools, but the technology is improving quickly. A separate review highlighted deep regression methods that model both cells and guttae as distance maps, allowing more precise differentiation between healthy tissue and diseased areas.²¹ Better imaging and measurement tools will be essential for evaluating newer therapies like DSO and cell injection, where subtle changes in cell density and morphology matter more than in traditional transplant follow-up.

What Patients Still Experience After Surgery

Even with the best current surgical option, DMEK, some visual complaints persist. A study tracking patient-reported symptoms found that glare, hazy vision, blurred vision, and daily fluctuations in vision were the most common complaints before surgery. All improved significantly after DMEK, but glare and fluctuating vision did not disappear entirely and lingered at low levels through follow-up.²² Standard visual acuity measurements did not correlate well with these subjective complaints, which means a patient can test well on the eye chart and still feel their vision is not right. This disconnect is one reason researchers are pursuing treatments that restore a more natural cell layer rather than grafting donor tissue, hoping that a regenerated or injected endothelium may produce fewer residual optical irregularities.

For patients considering their options today, the practical landscape looks roughly like this: mild to moderate Fuchs with central guttae and healthy peripheral cells may qualify for DSO, possibly enhanced with ROCK inhibitor drops. Advanced disease or limbus-to-limbus guttae still calls for DMEK. Cell injection therapy is available in select clinical trials and may become a mainstream option within the next several years. And for the first time, drugs targeting the underlying genetic defect are in human testing, raising the possibility that future patients might treat Fuchs dystrophy with an eye drop rather than surgery.

Three-Dimensional Corneal Imaging

Beyond specular microscopy, researchers have begun using three-dimensional anterior segment optical coherence tomography (OCT) to evaluate the corneal endothelium in Fuchs patients. A study measuring OCT reflectivity across different quadrants of the inner corneal surface found that reflectivity correlated positively with clinical severity grades and inversely with endothelial cell count and the percentage of hexagonal cells.²³ In other words, more reflective areas on the scan corresponded to sicker regions with fewer surviving cells. The study also found that individual quadrants of the cornea could behave somewhat independently, meaning the disease does not always progress uniformly. This kind of spatial mapping could eventually help surgeons plan DSO more precisely, targeting only the most affected zone and preserving as much healthy periphery as possible.